Cantor Fitzgerald Maintains 'Neutral' Rating on Amgen Stock

Analysts cite steady performance but lack of upside potential in the near term

Apr. 9, 2026 at 11:54am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of the inner workings of a large industrial banking machine, with intricate gears, levers, and mechanical components dramatically lit against a dark background, conceptually representing the institutional forces and infrastructure underlying financial markets.Amidst the complex machinery of the financial industry, Cantor Fitzgerald analysts see limited near-term upside for Amgen's stock performance.Thousand Oaks Today

Cantor Fitzgerald has reiterated its 'neutral' rating on shares of Amgen (NASDAQ:AMGN), the global biotechnology company, in a research report published on Wednesday. The firm maintained its $350 price target, citing the company's consistent financial performance but lack of significant upside potential in the near future.

Why it matters

As one of the largest and most influential research firms on Wall Street, Cantor Fitzgerald's rating and price target on Amgen stock carries significant weight with investors. The 'neutral' rating suggests the analysts see limited room for the stock to appreciate in the short term, despite the company's track record of delivering solid financial results.

The details

In the research report, Cantor Fitzgerald analysts noted that Amgen has a diversified commercial portfolio of biologic medicines used in oncology, supportive care, nephrology, bone health and cardiovascular disease. However, they did not identify any major near-term catalysts that could drive the stock price higher. The firm's $350 price target represents a modest premium to Amgen's current trading level.

  • Cantor Fitzgerald published the research report on Wednesday, April 9, 2026.

The players

Amgen

A global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. Amgen focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses.

Cantor Fitzgerald

A leading global financial services firm that provides institutional equity and fixed income sales and trading, investment banking, and research services.

Got photos? Submit your photos here. ›

The takeaway

Amgen's consistent financial performance and diversified product portfolio have not been enough to impress Cantor Fitzgerald analysts, who see limited upside potential for the stock in the near term. This neutral rating from a prominent Wall Street firm suggests investors may need to temper their expectations for significant share price appreciation from Amgen in the coming months.